Ocular toxicity of bortezomib therapy

Arias-Peso, Borja; Bakkali, Mohamed Bakkali El; Fernández, Álvaro Tello; Rodríguez-Marco, N.A.

doi:10.1016/j.jfo.2020.10.007

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma that has been associated with the development of blepharitis. Bortezomib-induced blepharitis is characterized by the presence of crusty debris along the eyelid margins, redness, and irritation [19].…”

Section: Blepharitis and Bortezomibmentioning

confidence: 99%

“…There is a hypothesis that bortezomib could hinder the ubiquitin pathway, resulting in the accumulation of proapoptotic molecules in the meibomian gland. This, in turn, could cause blepharitis and recurrent chalazia as secondary effects [19,20]. Simultaneously, bortezomib is known to affect other inflammatory pathways such as NF-kB, JAK/STAT, and MAP kinase, which can lead to the release of pro-inflammatory cytokines.…”

Section: Blepharitis and Bortezomibmentioning

confidence: 99%

See 1 more Smart Citation

Uncommon Blepharitis

Di Zazzo,

Giannaccare,

Villani

et al. 2024

JCM

View full text Add to dashboard Cite

Blepharitis is a common chronic inflammatory condition affecting the eyelid margins; the pathophysiology of blepharitis is complex and not fully understood. The disease is anatomically divided into anterior (inflammation of eyelashes) and posterior (meibomian gland dysfunction) types. Diagnosis relies on clinical examination, revealing characteristic features like scurf, vascular changes, and meibomian gland dysfunction. The main goals of blepharitis treatment are symptom relief, recurrence prevention, and complication risk minimization. Treatment options include lid hygiene, topical and systemic antibiotics, topical corticosteroids, and omega-3 supplements. However, it is important to highlight reported cases of blepharitis as side effects of systemic therapies, particularly in the context of chemotherapy, bortezomib, cetuximab, TNFα inhibitors, and dupilumab. It is crucial to monitor patients undergoing such treatments regularly and attentively in order to promptly set up adequate supportive therapy. Of even more importance is future research on the pathophysiological mechanisms responsible for the occurrence of these ocular side effects in order to find a nosological cure for the issue.

show abstract

Section: Blepharitis and Bortezomibmentioning

confidence: 99%

Section: Blepharitis and Bortezomibmentioning

confidence: 99%